Orexigen Therapeutics, Inc. (NASDAQ:OREX) shares decreased -8.76% in last trading session and ended the day at $0.64. OREX has a return on assets of -31.20%. Orexigen Therapeutics, Inc. (NASDAQ:OREX) quarterly performance is -62.21%.
Orexigen Therapeutics, Inc. (NASDAQ: OREX) announced Valeant Pharmaceuticals International, Inc. will commercialize Mysimba®(naltrexone HCl / bupropion HCl prolonged release) in Central and Eastern Europe. The distribution agreement between Valeant Holdings Ireland and Orexigen’s wholly owned subsidiary, Orexigen Therapeutics Ireland Ltd., includes 12 countries where Mysimba has been approved for marketing in the European Union (EU): Greece, Slovenia, Slovakia, Czech Republic, Hungary, Croatia, Lithuania, Estonia, Poland, Latvia, Bulgaria, and Romania. The agreement also extends to several non-EU countries where Valeant will apply for marketing authorization: Serbia, Bosnia and Herzegovina, Albania, Macedonia, Montenegro, Kosovo and Turkey. Orexigen expects Valeant to launch in the 12 EU countries in the second half of this year.
REX American Resources Corporation (NYSE:REX) ended the last trading day at $54.87. Company weekly volatility is calculated as 3.78% and price to cash ratio as 2.76. REX American Resources Corporation (NYSE:REX) showed a weekly performance of 2.48%.
REX American Resources Corporation (NYSE:REX), announced that it will report its fiscal 2015 fourth quarter financial results on Wednesday, March 23, 2016 pre-market and will host a conference call and webcast at 11:00 a.m. ET that morning to review the results.
On 15 March, FMC Corp. (NYSE:FMC) shares fell -2.37% and was closed at $39.12. FMC EPS growth in last 5 year was -20.10%. FMC Corp. (NYSE:FMC) year to date (YTD) performance is -0.03%.
FMC Corporation (NYSE:FMC) announced that its Board of Directors declared a regular quarterly dividend of 16.5 cents per share, payable on April 21, 2016, to shareholders of record at the close of business on March 31, 2016.
Aralez Pharmaceuticals Inc. (NASDAQ:ARLZ) shares fell -21.21% in last trading session and ended the day at $4.57. Aralez Pharmaceuticals Inc. (NASDAQ:ARLZ) quarterly performance is -29.48%.
Aralez Pharmaceuticals Inc. (NASDAQ:ARLZ) reported Total revenues for the three months ended December 31, 2015 were $6.0 million compared to $9.9 million for the three months ended December 31, 2014, which included $4.3 million of amortization of upfront licensing fees. VIMOVO® royalties for the three months ended December 31, 2015 were $6.0 million, which was an increase of 6% compared to $5.6 million for the three months ended December 31, 2014.
Perion Network Ltd. (NASDAQ:PERI) caters to the Technology space. It has a net profit margin of -25.80% and weekly performance is 1.72%. On the last day of trading company shares ended up at $2.36.
Perion Network Ltd. (NASDAQ:PERI) reported revenues were $65.3 million, as compared to $78.7 million in the fourth quarter of 2014. This decrease is primarily a result of our decision to significantly reduce Customer Acquisition Costs (“CAC”) since the third quarter of 2014 to focus on premium publishers, partially offset by a revenue increase from the one month of Undertone activity since its acquisition on November 30, 2015.
Leave a Reply